Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy
medicalxpress - Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and …
AI Summary: Researchers have identified decreased TXNRD1 and related molecular changes that appear linked to resistance against tagraxofusp in BPDCN patients. This insight exposes a plausible resistance mechanism and opens opportunities to test predictive biomarkers or combination strategies to overcome failure, which is welcome news for clinicians facing a stubborn, high‑risk disease.
Medieval babies and adults buried together in Sweden were not related, archaeologists discover — raising big questions about early Christian burial practices
livescience - In an unexpected discovery, researchers found that three medieval Swedish cemeteries held children buried with unrelated adults.
AI Summary: Archaeological and genetic analyses reveal medieval Swedish burial patterns that placed infants and children alongside unrelated adults, including female infants buried among men. The findings challenge assumptions about kinship‑based internment and suggest shifting funerary practices during early Christianization, prompting fresh questions about social identity and ritual in the period.
Parham Habibzadeh: ctDNA MRD After CRLM Resection Identifies Who Benefits From ACT!
oncodaily - Parham Habibzadeh, Internal Medicine Resident at UPMC, shared a post on X: “JAMA Oncology: ctDNA MRD after CRLM resection identifies who benefits from ACT! Upfront surgery: MRD+ patients improved with […]
AI Summary: A growing body of evidence shows circulating tumor DNA (ctDNA) measured after colorectal liver metastasis resection can identify which patients truly benefit from adjuvant chemotherapy and who likely do not. This blood test promises more personalized postoperative care, reducing unnecessary toxicity and costs by targeting chemo to molecular minimal residual disease rather than gut instinct.
For the First Time, a Cell Built From Scratch Grows and Divides
Yasemin Saplakoglu / quantamagazine - Scientists built a synthetic cell that combines more lifelike properties than ever before — proof of concept that it’s possible to bring nonliving materials to life, or something close to it, in the lab. The post For the First Time, a Cell Built From Scra…
AI Summary: Scientists have for the first time built a synthetic cell from scratch that completes a full life cycle — growing and dividing in the lab. The milestone demonstrates control over core cellular processes, opening doors for bespoke biomanufacturing and disease modelling, while reviving familiar ethical and biosafety questions. Yes, it’s breathtaking — and yes, we should probably be cautious.
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
Alexandros Rampotas, Zoë C. Wong, Isaac Gannon, Charlotte K. Brierley, Yuqi Shen, Camelia Benlabiod, / science - Science Translational Medicine, Volume 18, Issue 856, July 2026.
AI Summary: Preclinical studies show CAR‑T cells engineered to target mutant calreticulin selectively eliminate disease‑driving clones in xenografts and human organoid models of myelofibrosis. The results reveal a potentially curative approach for a previously intractable mutation‑driven disease, though safety, on‑target effects and clinical translation remain to be rigorously tested.
First use of precision editing to study human embryo development reveals role of master gene
medicalxpress - Research led by the University of Cambridge Loke Center for Trophoblast Research has shown that a genome-editing technique can be used to alter a single gene in human embryonic cells, enabling the study of very early human development in unparalleled deta…
AI Summary: Scientists used precision genome editing in human embryos to identify a 'master' developmental gene that triggers early human development stages. The finding clarifies key molecular steps, offering insights into congenital disorders and embryology, but also reignites ethical debate over experimental editing — cue the lab‑coat philosophers.
Early-onset cancers are on the rise: Knowing family history is crucial
medicalxpress - In the U.S., more than a dozen kinds of cancer are on the rise in adults under 50. Among these early-onset cancers, colorectal and breast cancers have increased the most, and colorectal cancer is now the deadliest cancer for Americans ages 18 to 49.
AI Summary: New analyses show early‑onset cancers are increasing and reinforce that detailed family history remains a key tool for risk assessment and targeted screening. Experts urged clinicians and health systems to prioritize family‑history collection and cascade testing to catch at‑risk individuals sooner and reduce preventable morbidity.
- Breast cancer risk: AI tools, polygenic scores, prevention (5)
- Colorectal cancer: rising cases and screening gaps worldwide (6)
- Faster biological aging linked to early-onset cancer rise (5)
- Inherited cancer risk and genomics driving early diagnoses (6)
- All Other Stories
Breast cancer risk: AI tools, polygenic scores, prevention
Colorectal cancer: rising cases and screening gaps worldwide
Faster biological aging linked to early-onset cancer rise
Inherited cancer risk and genomics driving early diagnoses
All Other Stories
Oldest known plague victims found in a 5,500-year-old burial ground in Siberia — and many of them were children
livescience - The oldest known evidence of the plague killing people has been found in Siberia, and it carried a gene that may have made it particularly deadly for children.
AI Summary: Archaeologists uncovered a 5,500‑year‑old burial site in Siberia containing victims of plague, many of them children, pushing the timeline of Yersinia pestis infections far earlier than previously thought. The discovery provides new clues about ancient disease spread and human vulnerability — and disproves the notion that pandemics are exclusively a modern pastime.
Some tumors eliminate healthy neighboring cells to grow, study reveals
medicalxpress - Chromosomal instability is a common feature in many solid tumors and is associated with greater aggressiveness. For years, its main contribution to cancer was thought to be driving the evolution of tumor genomes, causing cells to gain chromosomes with gro…
AI Summary: Researchers found some tumors actively eliminate neighboring healthy cells to expand and thrive, revealing a brutal but precise survival strategy. Understanding the molecular signals that drive this local cell clearance exposes new therapeutic targets — flip the mechanism and you may stop tumors in their tracks, or at least make cancer's arrogance its downfall.
In a First, Scientists Precisely Edit Human Embryo Genes
Carl Zimmer / nytimes - Researchers relied on a newer gene-editing technique that may make it possibl to engineer embryos, a prospect that has long alarmed bioethicists.
AI Summary: Researchers report the first precise edits to human embryo genes, demonstrating a technical milestone that immediately reopened the ethical and safety conversation about germline modification. Scientists urge caution, tighter oversight and more study before any clinical application while bioethicists debate whether we’ve crossed a line that’s been long teased in science fiction.
LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC
oncodaily - LIBRETTO-432 Trial was presented during ASCO 2026 by Jonathan W. Goldman, MD, as a global, multicenter, phase 3, double-blind, randomized, placebo-controlled study evaluating adjuvant selpercatinib in patients with early-stage RET […]
AI Summary: At ASCO26 plenary, LIBRETTO‑432 data show adjuvant selpercatinib markedly prolongs event‑free survival and slashes recurrence risk for patients with stage II–IIIA RET fusion–positive non‑small cell lung cancer after curative treatment. The findings support a new standard for this rare genetic subgroup and press the case for routine genomic testing.
One-time gene editing treatment lowers 'bad' cholesterol by up to 62%
medicalxpress - Patients in London have received a pioneering new gene editing therapy that lowers "bad" cholesterol after a single infusion, as part of a study involving UCL scientists.
AI Summary: Early clinical data show a one‑time gene‑editing infusion can reduce LDL cholesterol by as much as 62% in patients with severe hypercholesterolemia. The approach, still experimental, produced large lipid drops with early safety signals, hinting at a possible future one‑and‑done therapy for high‑risk cardiovascular patients — pending larger trials and careful long‑term follow‑up.
OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer
oncodaily - OPTIMA is one of the most important de-escalation studies presented at the 2026 ASCO Annual Meeting, because it addresses a daily clinical dilemma in early breast cancer: which patients truly […]
AI Summary: The OPTIMA trial demonstrated that using the Prosigna genomic test to select low‑risk ER+/HER2− early breast cancer patients allows omission of adjuvant chemotherapy without compromising disease control. The de‑escalation approach reduced exposure to chemo toxicity and supports molecular risk stratification to spare large numbers of patients unnecessary treatment — elegant, evidence‑based thrift.
Listen to the Latest ‘KFF Health News Minute’
kffhealthnews - The "KFF Health News Minute" brings original health care and health policy reporting from our newsroom to the airwaves each week.
AI Summary: A phase 2 study investigated FGFR inhibition with rogaratinib in succinate dehydrogenase–deficient gastrointestinal stromal tumors. Results reported tumor control in this rare molecular subset, offering a targeted therapeutic approach where options are sparse and validating FGFR as a biologic vulnerability in SDH‑deficient GIST.
Simple blood test could lead to personalized lung cancer treatment
medicalxpress - A single blood test could help doctors predict how lung cancer patients will respond to treatment before therapy begins, researchers have found. University of Queensland-led research focused on non-small cell lung cancer (NSCLC), the most common form of t…
AI Summary: Researchers describe a circulating cell-free methylated DNA liquid biopsy that can detect and track lung cancer by reading tumor-specific methylation patterns in blood. The minimally invasive test aims to guide personalized treatment choices, enable earlier detection of recurrence, and reduce dependence on tissue biopsies—basically doing the diagnostic heavy lifting while you sip your coffee.
- Blood tests for monitoring and personalizing lung cancer care (4)
- MCED trials and clinical benefit debate (4)
- Methylation liquid biopsy methods and applications (4)
- All Other Stories
Blood tests for monitoring and personalizing lung cancer care
MCED trials and clinical benefit debate
Methylation liquid biopsy methods and applications
All Other Stories
How state laws can stymie research into your ancestors' psychiatric records
abcnews - Frustrated family members and others have been pushing for law changes in New York and other states that would allow the release of mental health records of long-dead ancestors
AI Summary: Legal researchers warn that a patchwork of state statutes and privacy rules is blocking access to historical psychiatric records needed for family‑history and population‑level studies. The restrictions complicate efforts to understand intergenerational mental‑health patterns and hamper reproducible research, leaving scientists to navigate inconsistent consent, archival access, and litigation risks.
Deadly, highly venomous box jellyfish discovered near Singapore is a newfound species
livescience - Researchers identified a new species of box jellyfish and recorded a surprising range expansion for the Thai sea wasp after analyzing the morphology and DNA of a handful of jellies in Singapore.
AI Summary: Marine scientists have identified a previously unknown species of highly venomous box jellyfish off Singapore, based on morphological and genetic analyses. The finding expands knowledge of regional marine biodiversity and triggers public‑safety updates and clinical guidance for envenomation, because nothing says “summer beach read” like a creature that can ruin your day.
Overactive MYC helps tumors fix DNA breaks and resist chemotherapy, study finds
medicalxpress - A protein best known for driving cancer growth also helps damaged tumor cells survive by repairing their DNA, according to a new study that could influence how some cancers are treated.
AI Summary: New research reveals overactive MYC drives tumor cells to repair DNA breaks more efficiently, enabling resistance to chemotherapy. By illuminating the repair pathways MYC hijacks, the study identifies potential targets to reverse resistance and improve treatment responses — because apparently cancers read the manual on how to survive your best shot.
- MYC hijacks DNA repair to enable chemo resistance (4)
- Other molecular drivers of chemoresistance and genome instability (3)
- Tumor cell death and immunity shape chemotherapy outcomes (3)
- All Other Stories
MYC hijacks DNA repair to enable chemo resistance
Other molecular drivers of chemoresistance and genome instability
Tumor cell death and immunity shape chemotherapy outcomes
All Other Stories
Data-Driven Decision Support in Obesity Management Commission: enabling more equitable and personalized obesity care
Paul W. Franks / nature - Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04363-0Announced in this Comment and in collaboration with Nature Medicine is the convening of the Data-Driven Decision Support in Obesity Management Commission, to promote adequate sc…
AI Summary: A phase 1/2 study of CRISPR‑Cas9 CD33‑deleted allogeneic hematopoietic cell transplantation followed by gemtuzumab ozogamicin maintenance reports encouraging early signals in AML. The gene‑editing approach aims to protect donor cells from CD33‑targeted therapy, potentially enabling safer post‑transplant maintenance and offering a novel strategy to marry cellular engineering with targeted antibody therapy.
- CD33‑targeted transplant and post‑transplant maintenance (4)
- Safety and ethical scrutiny of gene editing and gene therapy (3)
- Scaling cell therapy: accreditation and expanding CAR indications (3)
- All Other Stories
CD33‑targeted transplant and post‑transplant maintenance
Safety and ethical scrutiny of gene editing and gene therapy
Scaling cell therapy: accreditation and expanding CAR indications
All Other Stories
Historical DNA Links Colonial Graves to 1.3 Million Living Relatives and May Have Identified the Colony’s Second Governor
discovermagazine - Learn how researchers used DNA and 23andMe to connect 17th-century Maryland colonists to more than 1.3 million living people and potentially identify the colony’s second governor.
AI Summary: Ancient DNA from a colonial‑era burial site has been analyzed and linked to living descendants, potentially identifying one of the colony’s leaders. Among the finds is an 8‑year‑old African American boy buried with white colonists; researchers report his presence but cannot yet determine whether he was enslaved, prompting fresh questions about social status and burial practices.